


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



The table below sets forth the relevant operating data and indicators of the Group's owned hospital by inpatients and outpatients for the three months (the second quarter) from April 1, 2022 to June 30, 2022 with comparative figures of the same period in 2021:

|                                                                                                                   | <b>Three months<br/>from April 1 to June 30,</b> |             |                                 |
|-------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|-------------|---------------------------------|
|                                                                                                                   | <b>2022</b>                                      | <b>2021</b> | <b>Year-on-year<br/>changes</b> |
| <b>Inpatients</b>                                                                                                 |                                                  |             |                                 |
| Number of inpatient bed-days                                                                                      | <b>786,633</b>                                   | 705,626     | 11.5                            |
| Average inpatient spending per bed-day on treatment and general healthcare services ( <i>RMB</i> )                | <b>337</b>                                       | 327         | 3.1                             |
| Average inpatient spending per bed-day on pharmaceutical sales ( <i>RMB</i> )                                     | <b>50</b>                                        | 53          | -5.7                            |
| <b>Total average inpatient spending per bed-day (<i>RMB</i>)</b>                                                  | <b>387</b>                                       | 380         | 1.8                             |
| <b>Outpatients</b>                                                                                                |                                                  |             |                                 |
| Number of outpatient visits ( <i>Note</i> )                                                                       | <b>112,752</b>                                   | 95,430      | 18.2                            |
| Average outpatient spending per visit on treatment and general healthcare services ( <i>RMB</i> ) ( <i>Note</i> ) | <b>123</b>                                       | 119         | 3.4                             |
| Average outpatient spending per visit on pharmaceutical sales ( <i>RMB</i> )                                      | <b>330</b>                                       | 303         | 8.9                             |
| <b>Total average outpatient spending per visit (<i>RMB</i>)</b>                                                   | <b>453</b>                                       | 421         | 7.6                             |

The above operating data are based on the Company's records and have not been audited or reviewed by the Company's auditors. The operating data may be different from those disclosed in periodical reports. The operating data disclosed in periodical reports shall prevail if there is any discrepancy. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

***Note: The above data of number of outpatient visits and average outpatient spending per visit on treatment and general healthcare services are excluding the business of the COVID-19 nucleic acid test.***

## **CONTINUED TRADING SUSPENSION**

At the request of the Company, trading in the shares of the Company on The Stock Exchange of Hong Kong Limited has been suspended with effect from 9:00 a.m. on April 1, 2022. Trading in the shares of the Company will remain suspended until further notice.

By order of the Board  
**Wenzhou Kangning Hospital Co., Ltd.**  
**GUAN Weili**  
*Chairman*

Zhejiang, the PRC  
 July 4, 2022

*As of the date of this announcement, the Company's executive directors are Mr. GUAN Weili, Ms. WANG Lianyue and Ms. WANG Hongyue; the non-executive directors are Mr. QIN Hao and Mr. LI Changhao; and the independent non-executive directors are Mr. ZHAO Xudong, Ms. ZHONG Wentang and Mr. LIU Ning.*